---
title: "Australian Clinical Labs Continues On-Market Share Buy-Back Program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279855514.md"
description: "Australian Clinical Labs Ltd (AU:ACL) has announced an ongoing on-market share buy-back program for its ordinary shares on the ASX, initially notified in October 2025. Recently, the company repurchased 81,675 shares, bringing the total to 6,056,533 shares. This buy-back aims to reduce shares on issue, enhance earnings per share, and signal management's confidence in the company's financial position. The latest analyst rating for AU:ACL is a Hold with a price target of A$2.40. The company operates in the healthcare sector, providing pathology and diagnostic services."
datetime: "2026-03-19T22:40:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279855514.md)
  - [en](https://longbridge.com/en/news/279855514.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279855514.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/279855514.md) | [繁體中文](https://longbridge.com/zh-HK/news/279855514.md)


# Australian Clinical Labs Continues On-Market Share Buy-Back Program

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an announcement.

Australian Clinical Labs has an on-market share buy-back in place for its ordinary fully paid shares on the ASX, as part of a capital management program first notified in October 2025. The latest daily update shows that the company repurchased 81,675 shares on the previous trading day, taking total buy-backs to 6,056,533 shares, which incrementally reduces shares on issue and can enhance earnings per share for remaining investors.

The company’s regular buy-back disclosures indicate an ongoing commitment to returning capital to shareholders and actively managing its balance sheet. Continued execution of the buy-back may support the share price and signal management’s confidence in the company’s financial position and future prospects, with implications for valuation and ownership concentration over time.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

**More about Australian Clinical Labs Ltd**

Australian Clinical Labs Ltd is an Australian-listed healthcare company that operates pathology and diagnostic laboratory services, with its ordinary fully paid shares trading on the ASX under the code ACL. The company services healthcare providers and patients through its network of clinical laboratories, positioning it within the medical diagnostics and pathology testing sector.

**Average Trading Volume:** 689,086

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$390.1M

For an in-depth examination of ACL stock, go to TipRanks’ Overview page.

### Related Stocks

- [Australian Clinical Labs Ltd (ACL.AU)](https://longbridge.com/en/quote/ACL.AU.md)

## Related News & Research

- [Australian Clinical Labs Director Sarah Butler Acquires Indirect Shareholding](https://longbridge.com/en/news/276412504.md)
- [Why healthcare is doing the heavy lifting in this job market](https://longbridge.com/en/news/280048926.md)
- [A hiring surge is coming as America prepares for a historic silver tsunami](https://longbridge.com/en/news/280168660.md)
- [A Look At Elis (ENXTPA:ELIS) Valuation After Recent Share Price Pullback](https://longbridge.com/en/news/280107903.md)
- [Glitch Shuts Australia's Biggest Maker Of Vital Fertilizer Input For 2 Months At Worst Possible Time](https://longbridge.com/en/news/280080854.md)